PTC Therapeutics (PTCT) Commences RG7916 Phase 2 in Type 2/3 SMA Patients with Roche, SMAF
- Wall Street falls ahead of inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- Synergy Pharma (SGYP) Trulance (Plecanatide) Approved by FDA
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
PTC Therapeutics, Inc. (Nasdq: PTCT) announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche (OTC: RHHBY) and the SMA Foundation (SMAF) initiated a Phase 2 study in pediatric and adult Type 2/3 SMA patients. The study, named SUNFISH, is a two-part study investigating the safety, tolerability and efficacy of RG7916, an oral small molecule survival motor neuron 2 (SMN2) splicing modifier. The first part of the study will evaluate safety and tolerability through escalating doses of RG7916. After dose selection, the study will transition into the pivotal second part evaluating the efficacy of RG7916. Initiation of the pivotal second part of the study is expected to begin in 2017 and will trigger a $20 million milestone payment to PTC from Roche. A similarly designed two-part study to evaluate RG7916 in Type I SMA patients is expected to begin in the coming months. SMA is a rare genetic disorder that results in neuromuscular disability beginning in infancy and is the leading genetic cause of mortality in infants and young children.
"We are excited to initiate clinical studies in SMA patients with RG7916 and advance our Spinal Muscular Atrophy program forward," said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. "An oral small molecule splicing modifier has the potential benefit of systemic exposure to promote SMN protein in all affected organs and tissues. This attribute, along with an ease of administration, provides promise for this program to have a meaningful benefit for SMA patients."
SUNFISH is a two-part clinical study. Part one is a double-blinded, placebo-controlled, randomized, exploratory dose-finding study in approximately 36 Type 2 and Type 3 pediatric and adult SMA patients for a minimum of 12 weeks. The primary objective of the first part of the study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RG7916 in patients, and to select the dose for the second part of the study. The pivotal second part is a double-blinded, placebo-controlled, randomized, confirmatory study in approximately 150 Type 2 and Type 3 SMA patients for up to 24 months, followed by an open-label extension. The primary objective of the pivotal second part of the study is to evaluate the efficacy of RG7916 compared to placebo.
A trial in Type I SMA patients, named FIREFISH, is planned to initiate in the coming months. FIREFISH is also planned to be a two-part study. The first part is an open-label, dose-escalation study in at least eight infants for a minimum of four weeks. The primary objective of part one of the study is to assess the safety profile of RG7916 in infants and determine the dose for part two. The second part of FIREFISH is expected to be an open-label, single-arm study in approximately 40 infants with Type I SMA for 24 months, followed by an open-label extension. The primary objective of the second part of the study will be to assess the efficacy of RG7916 at the selected dose after 12 months of treatment.
RG7916 directly targets the underlying molecular deficiency of SMA by modulating SMN2 splicing to increase expression of stable full-length SMN2 mRNA from the SMN2 gene. A healthy volunteer study was recently completed and the preliminary results demonstrate that RG7916 increased the production of full-length SMN2 mRNA further demonstrating proof of mechanism for oral small molecule SMN2 splicing modifiers. RG7916 was also well tolerated.
The SMA program was initially developed by PTC Therapeutics in partnership with the SMA Foundation in 2006 to accelerate the development of a treatment for SMA. In November 2011, Roche gained an exclusive worldwide license to the PTC/SMA Foundation SMN2 alternative splicing program. The development of these compounds is being executed by Roche and overseen by a joint steering committee with members from PTC, Roche, and the SMA Foundation.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan (AGN) Announces FDA Approval Of RHOFADE Cream to Treat Redness Associated with Rosacea
- PPG Industries (PPG) Names Vincent Morales to CFO
- Western Union (WU) Announces Agreements to Resolve U.S. Investigations
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!